207 related articles for article (PubMed ID: 33621099)
21. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
22. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
23. A systematic evaluation of Flow Field Flow Fractionation and single-particle ICP-MS to obtain the size distribution of organo-mineral iron oxyhydroxide colloids.
Moens C; Waegeneers N; Fritzsche A; Nobels P; Smolders E
J Chromatogr A; 2019 Aug; 1599():203-214. PubMed ID: 31047657
[TBL] [Abstract][Full Text] [Related]
24. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
25. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
26. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Warady BA; Seligman PA; Dahl NV
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1140-6. PubMed ID: 17942782
[TBL] [Abstract][Full Text] [Related]
27. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
[TBL] [Abstract][Full Text] [Related]
28. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure.
Krupnik L; Joshi P; Kappler A; Flühmann B; Alston AB; Digigow R; Wick P; Neels A
Eur J Pharm Sci; 2023 Sep; 188():106521. PubMed ID: 37423578
[TBL] [Abstract][Full Text] [Related]
29. A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering.
Di Francesco T; Borchard G
J Pharm Biomed Anal; 2018 Apr; 152():89-93. PubMed ID: 29414023
[TBL] [Abstract][Full Text] [Related]
30. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
31. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
[TBL] [Abstract][Full Text] [Related]
33. The presence of iron oxide nanoparticles in the food pigment E172.
Voss L; Hsiao IL; Ebisch M; Vidmar J; Dreiack N; Böhmert L; Stock V; Braeuning A; Loeschner K; Laux P; Thünemann AF; Lampen A; Sieg H
Food Chem; 2020 Oct; 327():127000. PubMed ID: 32454284
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs.
Sun Z; Jiang J; Chen X
Clin Pharmacokinet; 2020 Aug; 59(8):995-1004. PubMed ID: 32328977
[TBL] [Abstract][Full Text] [Related]
35. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
38. A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive factor of cardiovascular tolerability.
Marchitto N; Curcio A; Iannarelli N; Petrucci A; Romano A; Pironti M; Paparello PT; Raimondi G
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7776-7783. PubMed ID: 32744704
[TBL] [Abstract][Full Text] [Related]
39. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
40. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
